Bioquivalence of ciprofloxacin tablet formulations assessed in Indonesian volunteers

Yahdiana Harahap, B. Prasaja, E. Indriati, W. Lusthom, Lipin

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Aim: Determination of the bioequivalence of two ciprofloxacin tablet formulations (test formulation manufactured by Novell Pharmaceutical Laboratories, Indonesia, reference formulation from Quimica Farmaceutica Bayer, Spain). Subjects and methods: 24 healthy volunteers received each of the two ciprofloxacin formulations at a dose of 500 mg in a 2-way crossover design. Blood samples were obtained prior to dosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 h after drug administration. Plasma concentrations of ciprofloxacin were monitored using high-performance liquid chromatography over a period of 24 h after administration. The pharmacokinetics parameter AUC0-24h, AUC0-∞ and Cmax were tested for bioequivalence after log-transformation of data and ratios of tmax were evaluated non-parametrically. Results: The point estimates and 90% confidence intervals for AUC0-24h, AUC0-∞ and Cmax were 97.55% (92.71 - 102.6%), 97.63% (92.90 - 102.59%) and 95.84% (89.95 - 102.10%), respectively, satisfying the bioequivalence criteria of the European Committee for Proprietary Medicinal Products and the US Food and Drug Administration guidelines. Conclusion: These results indicate that two medications of ciprofloxacin are bioequivalent and, thus, may be prescribed interchangeably.

Original languageEnglish
Pages (from-to)373-376
Number of pages4
JournalInternational Journal of Clinical Pharmacology and Therapeutics
Volume45
Issue number6
Publication statusPublished - 1 Jun 2007

Keywords

  • Bioequivalence
  • Ciprofloxacin
  • Pharmacokinetics

Fingerprint Dive into the research topics of 'Bioquivalence of ciprofloxacin tablet formulations assessed in Indonesian volunteers'. Together they form a unique fingerprint.

Cite this